Document Detail


The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval.
MedLine Citation:
PMID:  16098435     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: This study was designed to evaluate effects of tadalafil, a phosphodiesterase-5 inhibitor used for the treatment of erectile dysfunction (ED), on the QT interval. BACKGROUND: Cardiovascular disease is common in men with ED. Men with cardiovascular disease and ED may have decreased cardiac repolarization reserve. METHODS: Effects of tadalafil (100 mg by mouth), ibutilide (0.002 mg/kg intravenously), and placebo on the QT interval in healthy men were compared (placebo and tadalafil [n = 90], with a subset [n = 61] receiving all treatments; mean age 30 years, range 18 to 53 years). Electrocardiographic sampling was done for two days before treatment and on treatment days. The QT was corrected for RR interval with five correction methods, including an individual correction (QTcI). Plasma concentrations of tadalafil were measured to evaluate concentration-QT effect relationships. RESULTS: At the time corresponding to maximum plasma concentration of tadalafil, the mean difference in the change in QTcI between tadalafil and placebo was 2.8 ms; tadalafil was equivalent to placebo (a priori, upper limit of 90% confidence interval < 10 ms [actual = 4.4 ms]; post hoc, upper limit of 95% confidence interval < 5 ms [actual = 4.8]). The active control, ibutilide, significantly increased QTcI by 6.9 and 8.9 ms compared with tadalafil and placebo, respectively. Similar statistical results were obtained with four additional QT correction methods. No subject had a QTcI > or = 450 ms or an increase in QTcI > or = 30 ms with any treatment. CONCLUSIONS: Based on the a priori statistical test of equivalence, placebo and high-dose tadalafil produced equivalent effects on the QT interval. This study reliably discerned 5- to 10-ms changes in corrected QT in the ibutilide active control group.
Authors:
Charles M Beasley; Malcolm I Mitchell; Alex A Dmitrienko; Jeffrey T Emmick; Wei Shen; Timothy M Costigan; Alun W Bedding; Michael A Turik; Arash Bakhtyari; Margaret R Warner; Jeremy N Ruskin; Louis R Cantilena; Robert A Kloner
Related Documents :
11971125 - Randomized controlled trials to assess therapies for multiple sclerosis.
18954485 - Endorsement of self-report neurovegetative items of depression is associated with multi...
14586605 - Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis?
19241295 - Relationships among anxiety, depression, and executive functioning in multiple sclerosis.
15631355 - Effects of antidepressant mirtazapine on fibromyalgia symptoms.
23257685 - Sputum hyaluronan and versican in severe eosinophilic asthma.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  46     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-08-15     Completed Date:  2005-09-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  678-87     Citation Subset:  AIM; IM    
Affiliation:
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA. cmbeasleyj@lilly.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Anti-Arrhythmia Agents / pharmacology*
Carbolines / adverse effects*,  pharmacology
Case-Control Studies
Electrocardiography*
Electrophysiology
Erectile Dysfunction / drug therapy
Humans
Long QT Syndrome
Male
Middle Aged
Phosphodiesterase Inhibitors / adverse effects*,  pharmacology
Placebos
Sulfonamides / pharmacology*
Time Factors
Ventricular Function / drug effects*
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Carbolines; 0/Phosphodiesterase Inhibitors; 0/Placebos; 0/Sulfonamides; 0/tadalafil; 130350-52-6/ibutilide
Comments/Corrections
Comment In:
J Am Coll Cardiol. 2005 Aug 16;46(4):688-9   [PMID:  16098436 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Electrogram characteristics in postinfarction ventricular tachycardia: effect of infarct age.
Next Document:  Prevalence and clinical significance of left atrial remodeling in competitive athletes.